Juno Therapeutics

Juno Therapeutics (acquired by Celgene/Bristol-Myers Squibb) was an early leader in CAR-T cell therapy development before acquisition. The company's trials helped define safety protocols for cellular immunotherapies. Juno's acquisition reflected the strategic importance of cell therapy capabilities for large pharmaceutical companies.